AptarGroup

Q2 FY2026 EarningsQ2 FY26 performance was mixed compared to consensus: net sales of $1,027M slightly beat the $1,012M expectation (+1.48%), but Adjusted EPS of $1.42 was roughly in-line with the normalized mean of $1.35 (normalized EPS $1.42 vs. $1.35 mean). Profitability faced headwinds as gross margin (35.6% actual vs. 36.1% expected) and EBIT missed consensus, primarily driven by unfavorable product mix in Pharma and operational ramp-up costs in Closures. Q3 FY26 EPS guidance of $1.45–$1.53 is generally supportive of current consensus, though margin compression remains a key watchpoint.